T-Therapeutics
The company’s proprietary transgenic mouse platform OpTiMus® provides unique, antigen-specific, human, therapeutic-grade TCRs directed at multiple target classes — many for the first time. T-Therapeutics is leveraging its world-class expertise in mouse genome engineering, drug development, single-cell genomics, machine learning and structural biology to develop a first-in-class drug pipeline and advance transformative precision medicines.
In 2023 T-Therapeutics raised $59m Series A money for its T cell receptor therapies, initially for cancer indications. Investors include Cambridge Innovation Capital, Soffinova Partners, University of Cambridge, F-Prime, Digitalis Ventures and Sanofi Ventures. The company and its world-class investors believe they are in on the ground floor of a massive new TCR therapeutics market.
Biopharma industry veteran, founder of Medivation and serial entrepreneur, Dr David Hung became chairman of T-Therapeutics in June 2024.
